Current Report Filing (8-k)
January 19 2021 - 4:30PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 12, 2021
AIKIDO
PHARMA INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-05576
|
|
52-0849320
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
One
Rockefeller Plaza, 11th Floor, New York, NY
|
|
10020
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (703) 992-9325
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, $0.0001 par value
|
|
AIKI
|
|
The
Nasdaq Capital Market
|
Item
5.07 Submission of Matters to a Vote of Security Holders.
On
January 12, 2021, AIkido Pharma Inc., a Delaware corporation (the “Company”), reconvened its 2020 annual meeting of
stockholders (the “Meeting”). At the Meeting, the Company’s did not obtain the approval from stockholders that
held a majority of the issued and outstanding shares of common stock as of the record date that was set for determination of stockholders
entitled to notice and to vote at the Meeting of the proposal to amend the Company’s amended and restated certificate of
incorporation (the “Amended and Restated Certificate of Incorporation”) to effect a reverse stock split of the Company’s
common stock to a ratio of up to one-for-ten.
Set
forth below are the final voting results for each of the proposals:
Proposal
No. 1 – Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse
stock split of the Company’s common stock at a ratio of one-for-ten
The
proposed amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of
the Company’s common stock at a ratio of one-for-ten. The voting results were as follows:
For
|
|
Against
|
|
Abstain
|
|
Broker
Non-Votes
|
15,037,931
|
|
7,388,845
|
|
129,586
|
|
N/A
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AIKIDO
PHARMA INC.
|
|
|
|
By:
|
/s/
Anthony Hayes
|
|
Name:
|
Anthony
Hayes
|
|
Title:
|
Chief
Executive Officer
|
Dated:
January 19, 2021
2
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Jul 2023 to Jul 2024